OverviewChartNewsTraderScreen

Goldman Sachs Put 50 SNW 19.12.20.../  DE000GG1NAJ7  /

EUWAX
17/05/2024  11:30:14 Chg.-0.001 Bid22:00:43 Ask22:00:43 Underlying Strike price Expiration date Option type
0.054EUR -1.82% -
Bid Size: -		 -
Ask Size: -		 SANOFI SA INHABER ... 50.00 EUR 19/12/2025 Put
GlobeNewswire 17/05 Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and ...
GlobeNewswire 13/05 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 13/05 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
TeleTrader 13/05 Europe mixed at open as CPI prints loom
GlobeNewswire 13/05 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 10/05 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 10/05 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 10/05 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire 09/05 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
TeleTrader 09/05 Europe opens mixed with BoE in focus
GlobeNewswire 08/05 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 07/05 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 02/05 Regeneron Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 02/05 Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire 30/04 Press Release: Annual General Meeting of April 30, 2024
TeleTrader 25/04 Europe opens mostly down after corporate earnings
TeleTrader 25/04 Europe down in premarket as financial results pour in
TeleTrader 25/04 Sanofi books net sales of €10.5B in Q1, up 2.4%
GlobeNewswire 25/04 Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire 23/04 Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire 17/04 IGM Biosciences Announces Refocusing of Sanofi Collaboration
GlobeNewswire 17/04 Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...
GlobeNewswire 16/04 2024 DTA Summit Agenda is LIVE!!
GlobeNewswire 10/04 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire 09/04 Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...